Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07599930

Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being

This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.

Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.

Main research questions:

Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This double-blind, randomised, placebo-controlled crossover trial will assess the effects of daily consumption for 4 weeks of a novel phytochemical- and fibre-rich granola snack created by TulaCode on menopausal symptoms. The effects of the snack will be compared to a calorie-matched placebo snack: a commercially available oat bar low in fibre and polyphenols. The study will also examine the impact of the intervention snack on mood, stress, sleep quality, cognition, depression and anxiety. Participants will be randomly assigned to either the intervention or the placebo snack for 4 weeks followed by a 4-week washout period before crossing over to the alternate snack for another 4 week period. Snacks will be consumed twice daily, and participants will be instructed to maintain their usual diet and physical activity while avoiding additional probiotic, prebiotic, or polyphenol-rich supplements throughout the study.

Participants will attend 4 in-person study visits at King's College London. At baseline, after 4 weeks, after 8 weeks (washout period) and after 12 weeks. Each study visit will take approximately 1 hour. On the day before each study visit, participants will be asked to self-collect their saliva, 24-h urine and stool samples at home, as well as finish a set of online questionnaires, and be fasted for 12 hours prior to their study visit.

Self-collection procedure of participants at home one day before study visits:

  • Collect a total of 6 saliva samples throughout the day to measure cortisol levels and fill the saliva collection booklet.
  • Collect a 24 h urine sample, starting in the morning after the first void urine, and finishing the next day collecting the first urine of the day (morning of the study visit day).
  • Collect a small stool sample throughout the day for gut microbiome analysis.
  • Fill the below online questionnaires:
  • Positive and Negative Affect Schedule (PANAS-SF) questionnaire
  • Hospital Anxiety and Depression Scale (HADS)
  • Menopause Rating Scale (MRS)
  • Cognitive Failure Questionnaire (CFQ)
  • Perceived Stress Scale (PSS)
  • World Health Organisation Quality of Life assessment instrument (EF-WHOQOL-100)
  • Weekly questionnaire, 4 questionnaires per visit:
  • International Physical Activity Questionnaire (IPAQ)
  • Pittsburgh Sleep Quality Index (PSQI)
  • Online 24 h dietary recall (Intake 24)
  • 24h picture log of meals (OPIS)
  • Gastrointestinal Symptom Rating Scale (GSRS)
  • Menopause Rating Scale (MRS)
  • Fill the below paper questionnaires:
  • Food-Frequency Questionnaire - EPIC (only for visit 2)
  • Food-Frequency Questionnaire - KCL polyphenol (only for visit 4)

On the morning of each study visit day, participants will bring their self-collected saliva, urine, and stool samples. Any Adverse events will be discussed and recorded. Any concomitant medication will be checked by the researchers that may impact on the eligibility criteria and the early completion of the study. Self-collected samples and completed online questionnaires will be checked. Blood pressure, heart rate and anthropometric measurements will be performed, waist-hip circumference will be measured, and fasting blood samples will be collected.

On Visit 1 (baseline), either intervention snack or a calorie-matched placebo snack will be provided to participants, with the amount should be enough for the 4-week study period. On Visit 3 (after 8 weeks), the crossover snacks will be provided to participants.

At the end of visit 1, 2 and 3, new self-collection kits and a link of online questionnaires will be distributed to participants to be used for next study visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 40 to 55
  • Score 14 or higher on the Menopause Rating Scale
  • For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.

Exclusion criteria

  • People who consume more than 15g of fibre a day
  • People who consume more than 2 cups of coffee or tea a day
  • People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day
  • People who do not have any intolerances or allergies to the following:
  • Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts
  • Chia seeds
  • Pumpkin seeds
  • Sunflower seeds
  • Dates
  • Gluten
  • Dairy
  • Oats
  • Barley
  • Soya
  • People who smoke or vape or have smoked or vaped in the last 2 years
  • People who consume more than 21 drinks a week or have a history of excess alcohol intake
  • People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems
  • People receiving drug treatment for lipid metabolisms (e.g., statins)
  • People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin
  • People taking antihypertensive drugs
  • People who take antibiotics or bacterial agents (Probiotics) within 1 month
  • People who take vitamin/dietary supplements within 1 month
  • Pregnant women, women ready for pregnancy, and nursing mothers
  • cardiac arrhythmia
  • renal failure
  • heart failure (NYHA II-IV)
  • diabetes mellitus
  • Malignant disease
  • People who have participated in a biomedical study within the past 3 months
  • Women who require hormone replacement therapy during the development of the protocol.

Treatment and study plan

Functional Snacks

Dietary Supplement

A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt

Placebo Snacks

Other

A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)

Primary outcomes

  1. Changes in menopause rating scale (MRS) of perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess menopause-related symptoms of perimenopausal women, using the menopause rating scale (MRS). The scale consists in 11 items ranging from 0 (none) to 4 (very severe).

Secondary outcomes

  1. Changes in subjective (perceived) stress level of perimenopausal women

    Time frame: Baseline & 4 weeks

    The subjective stress level of perimenopausal women are assessed using the Perceived Stress Scale (PSS) questionnaire. The scale consists in 10 items rated on a 5-point Likert scale.

  2. Changes in affect in perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess the affect of perimenopausal women, using the Positive and Negative Affect Schedule (PANAS-SF) questionnaire, consisting of 20 items rated from 1 (very slightly or not at all) to 5 (extremely).

  3. Changes in female sex hormone levels of perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess the female sex hormone levels of perimenopausal women, measured several esterone levels in blood samples using the randox clinical biochemistry analyser.

  4. Changes in cognitive function of perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess cognitive function of perimenopausal womenm using Cognitive Failures questionnaire (CFQ). The questionnaire consists of 25 questions rated on a 5-point Likert scale from 0 ("Never") to 4 ("Very often").

  5. Changes in mental health and wellbeing metabolites level of perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess the metabolites related to mental health and wellbeing of perimenopausal women, measured a pack of metabolites/compounds including gut-brain axis metabolites, inflammatory markers, short-chain fatty acid, in plasma samples using Randox clinical biochemistry analyser and LC-MS.

  6. Habitual diet of perimenopausal women

    Time frame: Baseline only

    Habitual diet is assessed via the food frequency questionnaire (FFQ), items ranging from "never" to "multiple times a day"-they consumed specific food and beverage items from a predefined list

  7. Gut microbiome of perimenopausal women

    Time frame: Baseline & 4 weeks

    To investigate the role of the gut microbiome on the perimenopause symptoms. Gut microbiome diversity and composition will be analysed using 16s RNA sequencing technique as a pack.

  8. Changes in hormonal stress levels in perimenopausal women

    Time frame: Baseline & 4 weeks

    Stress measured as the cortisol level changes in saliva samples by LC-MS, including the cortisol levels at 0 min, 15 min, 30 min and 60 min after wakening and 12 pm and 8 pm on the day.

  9. Changes in mood in perimenopausal women

    Time frame: Baseline & 4 weeks

    To assess the overall changes in mood, using the Hospital Anxiety and Depression Scale (HADS), consist of 14 items rated on a 0-21 scale, with a higher score indicates a severe symptom.

  10. Changes in sleep quality in perimenopausal women

    Time frame: Weekly from baseline to 4 weeks

    Sleep quality changes measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire, consist of 19 items rated on a 0-3 scale with higher scores indicating poorer sleep quality.

  11. Changes in physical activity level in perimenopausal women

    Time frame: Weekly from baseline to 4 weeks

    Changes in physical activity measured using the International Physical Activity questionnaire (IPAQ), producing a total activity score expressed in metabolic equivalent minutes per week (MET-min/week).

  12. Changes in quality of life in perimenopausal women

    Time frame: Baseline & 4 weeks

    Changes in quality of life measured using the World Health Organisation Quality of Life Assessment Instrument (EF-WHOQOL-100), a 100 item questionnaire with responses rated on a 1-5 Likert scale

  13. Changes in gastrointestinal symptoms of perimenopausal women

    Time frame: Weekly from baseline to 4 weeks

    Changes in the gastrointestinal function measured using Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, consisting of 15 items rated from 1 (no discomfort) to 7 (very severe discomfort).

  14. Changes in weight of perimenopausal women

    Time frame: Baseline & 4 weeks

    Weight will be measured in kilograms using a body composition analyser (Tanita BC-418 MA)

  15. Height of perimenopausal women

    Time frame: Baseline

    Height in centimeters will be measured using a stadiometer

  16. Changes in BMI of perimenopausal women

    Time frame: Baseline & 4 weeks

    Changes in BMI will be measured by weighing participants using the body composition analyser (Tanita BC-418 MA) and calculating BMI from participant height and weight

  17. Changes in hip-waist circumference of perimenopausal women

    Time frame: Baseline & 4 weeks

    Hip and waist circumference will be measured in centimeters using a measuring tape

  18. Changes in blood pressure of perimenopausal women

    Time frame: Baseline & 4 weeks

    Blood pressure will be measured using an electric sphygmomanometer blood pressure monitor in millimeters of mercury (mmHg).

  19. Heart rate of perimenopausal women

    Time frame: Baseline & 4 weeks

    Heart rate will be measured in beats per minute using an electric sphygmomanometer blood pressure monitor

  20. Dietary polyphenol intake of perimenopausal women

    Time frame: Baseline

    Polyphenol intake measured via the Food-Frequency Questionnaire - Polyphenol. Food items are rated from "Never" to "More than 6 times per day".

  21. Weekly diet of perimenopausal women

    Time frame: Weekly from baseline to week 4

    Weekly diet using Intake24, an online 24-hour dietary recall system that records all foods and drinks consumed during the previous day. It uses portion-size images and structured prompts to improve accuracy and reduce under-reporting.

  22. Weekly diet of perimenopausal women

    Time frame: Weekly from baseline to week 4

    Weekly diet will be measured using OPIS, a mobile application using artificial intelligence to estimate the nutrients and components of meals. Participants take a picture of their meals for 24 hours in the application and AI breaks down the make-up of the food.

Other outcomes

  1. Plasma and Urinary metabolites of (poly)phenols of perimenopausal women

    Time frame: Baseline and 4 weeks

    In total more than 160 phenolic compounds and phase 2 metabolites will be measured in plasma and urine samples by LC-MS.

Study contacts

Contact information is provided by the study sponsor or research team.

Ana Rodriguez-Mateos, PhD

CONTACT

[email protected]

+44 (0)20 7848 4349 ext. 84349

Zicheng Zhang, PhD

CONTACT

[email protected]

+44 (0)20 7848 0313 ext. 80313

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Tulā Code Ltd

Registry information

Official study title

Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial

Acronym: SWAP

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 20, 2026
Registry last updated
May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.